In 2009, administrators at St. Joseph Medical Center in Maryland wrote letters to patients of Mark Midei, informing them that its staff cardiologist may have subjected them to a coronary artery stenting procedure inappropriately. That communication prompted an article in a local newspaper, which triggered an investigation by the Senate Finance Committee.
The Committee subsequently released a report which asserted that Midei performed nearly 600 stenting procedures unnecessarily, and charged Medicare nearly $4m for these procedures. According to the report, all the procedures involved stents made by Abbott Labs. Abbott, in turn, had paid Midei $31,000, added him to its roster of top stent volume cardiologists, and feted him with a pig roast at his home to celebrate a prodigious day in which he implanted 30 stents (apparently a company record). Then, after St. Joseph’s dropped Midei from its roster, Abbott hired him to provide services in Japan and China. In the subsequent year, the number of patients who received stents at the hospital fell to 116 from 350 in the previous year.
Most recently, the Maryland Board of Physicians revoked Midei’s license to practice medicine after concluding that he did implant stents into the coronary arteries of 4 patients inappropriately. The Board also determined that he exaggerated the severity of coronary blockages, and claimed incorrectly that they had unstable angina. Midei has denied the allegations and sued St. Joseph for damaging his career.
The Context Read more »
*This blog post was originally published at Pizaazz*
The end of the year marks a time for list-intensive posts. Recently Larry Husten from CardioExchange and CardioBrief asked for my opinion on the three most important cardiology-related news stories of 2010. Additionally, he wanted three predictions for 2011. Here goes:
Top Cardiology Stories Of 2010:
1. By far, the #1 heart story of 2010 was the release of the novel blood-thinning drug dabigatran (Pradaxa) for the prevention of stroke in atrial fibrillation. Until this October, the only way to reduce stroke risk in AF was warfarin, the active ingredient in rat poison. Assuming that there aren’t any post-market surprises, Pradaxa figures to be a true blockbuster. Doctors and patients have waited a long time to say goodbye to warfarin.
2. The Dr. Mark Midei stent story: Whether Dr. Midei is guilty or innocent of implanting hundreds of unnecessary stents isn’t really the big story. The real impact of this well-chronicled saga is the attention that it brings to the therapeutic misconceptions of coronary stenting. The problem with squishing and stenting is that although they improve the physics (of bloodflow), they do not change the biology of arterial disease — a hard concept to grasp when staring at a picture of a partial blockage. The vast press coverage of Dr. Midei’s alleged transgressions has served to educate many about heart disease, the nation’s #1 killer. Read more »
*This blog post was originally published at Dr John M*
Researchers at Lund University in Sweden successfully used magnets to guide clot-dissolving drugs (fibrinolytics) directly to the site of a thrombus stuck within a coronary stent. They did this by attaching the drugs to magnetic nanoparticles and using external magnets to move them to the right spot.
From the press release:
Guiding drug-loaded magnetic particles using a magnet outside the body is not a new idea. However, previous attempts have failed for various reasons: It has only been possible to reach the body’s superficial tissue, and the particles have often obstructed the smallest blood vessels.
The Lund researchers’ attempt has succeeded partly because nanotechnology has made the particles tiny enough to pass through the smallest arteries and partly because the target has been a metallic stent. When the stent is placed in a magnetic field, the magnetic force becomes sufficiently strong to attract the magnetic nanoparticles. For the method to work the patient therefore has to have an implant containing a magnetic metal.
Press release: Medicine reaches the target with the help of magnets…
Abstract in Biomaterials: The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy.
*This blog post was originally published at Medgadget*